DOT™ Lenses Worn by One Million Children

Rapid Adoption Affirms Growing Need, Demonstrated Benefits,
and Professional-Patient Trust in Unique Contrast Management -Based Design

DALLAS, August 21, 2025—Diffusion Optics Technology™ (DOT^™) spectacle lenses have been worn by one million children to control their myopia—a major milestone that reflects the critical need for myopia control solutions and the strong performance and trust in DOT^™ lenses’ unique design.^*

DOT™ lenses, developed by SightGlass Vision, first became available in 2021 and have since gained significant momentum. With launches across Asia-Pacific, Europe, and North America, over 500,000 children are estimated to have been fitted with DOT™ lenses in 2025 alone, based on global sales data.

The design of DOT™ lenses is underpinned by contrast management. High artificial contrast levels in the modern visual environment may be linked to accelerated eye growth that results in the progression of myopia.¹ DOT™ lenses mimic more natural contrast environments by incorporating thousands of elements that gently scatter light before it reaches the retina.²

Clinical studies have demonstrated that DOT™ lenses can slow average myopia progression by up to 75% after 12 months of wear across diverse populations.^2,3,‡ The lenses are more than just effective, in fact 93% of children said they love their glasses with DOT™ lenses.^4,5,‡

“Reaching one million children is a powerful testament to what our clinical studies have already shown—DOT™ lenses work, eye care professionals trust them, and children want to wear them,” said Andrew Sedgwick, CEO of SightGlass Vision. “It’s encouraging to see eye care professionals increasingly embrace this innovation for their young patients, marking another meaningful step towards combatting the global myopia epidemic. We remain committed to bringing DOT™ lenses to children in more parts of the world.”

SightGlass Vision’s patent-protected technology has made its commercial debut in several markets, including China, the Netherlands, Israel, Canada, and Spain, as well as through preliminary market trials in other countries. ^† Founded in 2016, SightGlass Vision  a joint venture of CooperCompanies and EssilorLuxottica. For more information, visit SightGlassVision.com.

###

About SightGlass Vision 

SightGlass Vision develops innovative technologies and science-based treatments to address the global myopia epidemic, backed by novel and comprehensive research. Its unique Diffusion Optics Technology™️ is based on ground-breaking discoveries surrounding myopia progression. Spectacle lenses using its patent-protected approach incorporate thousands of light-scattering elements designed to mimic more natural contrast on the retina — a method intended to reduce myopia progression in children. The treatment has completed the three years pivotal multisite clinical study. Founded in 2016, the company now operates as a joint venture of CooperCompanies and EssilorLuxottica to accelerate commercialization opportunities and expand the myopia management category worldwide.

*This figure is based on sales data and reflects global usage across multiple regions.

^†SightGlass Vision™ Diffusion Optics Technology™ spectacle lenses are not available for sale in the United States.

^‡Patient population aged 6–10 years (CYPRESS) and 6–13 years (CATHAY). Lenses were worn 10 hours per day.​